

Gilead Sciences - Creating Value and Promising Growth for Long Term

<https://marketpublishers.com/r/GA6165CC57AEN.html>

Date: July 2012

Pages: 9

Price: US\$ 140.00 (Single User License)

ID: GA6165CC57AEN

Abstracts

Gilead (GILD) continues to dominate in the HIV space and poised to repeat the feat in HCV, and supremacy in the HIV space in 2012-18 should remain intact with the successful launch of Complera/ Eviplera (truvada + edurant, 2Q12A: \$72m), Quad Pill (R, truvada + Cobicistat +Elvitegravir) by YE12 and Elvitegravir (R, Integrase inhibitor) in 1H13. Approval in HIV infection risk reduction (pre-exposure prophylaxis, PrEP) of Truvada should further accelerate the growth. Clarity on IFN-free combination options' GS-7977/GS-5885 (Polymerase Inhibitor, PMI +NS5A inhibitor) as a single tablet regimen (STR) in HCV suggests GILD's confidence in its in-house HCV portfolio. We expect GILD to lead in this area with launch expected in... For further detail, please read our report released on 31st July, 2012, titled, "Creating Value and Promising Growth for Long Term".

I would like to order

Product name: Gilead Sciences - Creating Value and Promising Growth for Long Term

Product link: <https://marketpublishers.com/r/GA6165CC57AEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA6165CC57AEN.html>